FDA
approval
· 2019-06-12
FDA Approved: DIOVAN HCT — Supplemental Application (Novartis Pharmaceuticals Corporation)
Summary
FDA approved a supplemental application for Diovan HCT (valsartan/hydrochlorothiazide) submitted by Novartis Pharmaceuticals Corporation.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
SUPPL AP for DIOVAN HCT (VALSARTAN AND HYDROCHLOROTHIAZIDE)